Morningstar

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

ATLANTA, Oct. 13, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Neurology has published results from a multicenter retrospective chart review study of ...
Finanznachrichten

UCB: Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

First published data from a multicenter retrospective chart review study to explore the safety and efficacy of pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 ...